The discovery of indole derivatives as novel hepatitis C virus inhibitors. 2016

Zhiqiang Han, and Xiao Liang, and Yaxin Wang, and Jie Qing, and Lin Cao, and Luqing Shang, and Zheng Yin
State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People's Republic of China.

In this study, a library of in-house small molecule was screened using a HCV cell-based assay and a compound (1) containing an N-protected indole scaffold (NINS) was identified as a novel anti-HCV inhibitor. Through structure activity relationship (SAR) study, it was observed that the racemic inhibitor (10m) displayed good anti-HCV activity (EC50 = 1.02 ± 0.10 μM) with the excellent selectivity index (SI = 45.56). Interestingly, R-enantiomer ((R)-10m) showed better anti-HCV activity and lower cytotoxicity than S-enantiomer ((S)-10m). (R)-10m gave the best anti-HCV potency (EC50 = 0.72 ± 0.09 μM) with the highest selectivity index (SI > 69.44). In addition, the mechanism of action study of NINS derivatives demonstrated that NINS derivatives interfere with the early step (viral entry) of the HCV life cycle.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D016174 Hepacivirus A genus of FLAVIVIRIDAE causing parenterally-transmitted HEPATITIS C which is associated with transfusions and drug abuse. Hepatitis C virus is the type species. Hepatitis C virus,Hepatitis C-Like Viruses,Hepaciviruses,Hepatitis C Like Viruses,Hepatitis C viruses,Hepatitis C-Like Virus

Related Publications

Zhiqiang Han, and Xiao Liang, and Yaxin Wang, and Jie Qing, and Lin Cao, and Luqing Shang, and Zheng Yin
July 2009, Bioorganic & medicinal chemistry letters,
Zhiqiang Han, and Xiao Liang, and Yaxin Wang, and Jie Qing, and Lin Cao, and Luqing Shang, and Zheng Yin
September 2018, Journal of medicinal chemistry,
Zhiqiang Han, and Xiao Liang, and Yaxin Wang, and Jie Qing, and Lin Cao, and Luqing Shang, and Zheng Yin
June 2019, MedChemComm,
Zhiqiang Han, and Xiao Liang, and Yaxin Wang, and Jie Qing, and Lin Cao, and Luqing Shang, and Zheng Yin
August 2020, Journal of medicinal chemistry,
Zhiqiang Han, and Xiao Liang, and Yaxin Wang, and Jie Qing, and Lin Cao, and Luqing Shang, and Zheng Yin
November 2021, Drug development research,
Zhiqiang Han, and Xiao Liang, and Yaxin Wang, and Jie Qing, and Lin Cao, and Luqing Shang, and Zheng Yin
May 2009, Journal of medicinal chemistry,
Zhiqiang Han, and Xiao Liang, and Yaxin Wang, and Jie Qing, and Lin Cao, and Luqing Shang, and Zheng Yin
March 2013, Journal of medicinal chemistry,
Zhiqiang Han, and Xiao Liang, and Yaxin Wang, and Jie Qing, and Lin Cao, and Luqing Shang, and Zheng Yin
September 1997, Biochemical and biophysical research communications,
Zhiqiang Han, and Xiao Liang, and Yaxin Wang, and Jie Qing, and Lin Cao, and Luqing Shang, and Zheng Yin
January 2015, European journal of medicinal chemistry,
Zhiqiang Han, and Xiao Liang, and Yaxin Wang, and Jie Qing, and Lin Cao, and Luqing Shang, and Zheng Yin
July 2023, Journal of medicinal chemistry,
Copied contents to your clipboard!